TW-37

For research use only. Not for use in humans.

製品コードS1121

TW-37化学構造

CAS No. 877877-35-5

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 26200
JPY 28500
JPY 114800
JPY 247600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(42)

製品安全説明書

Bcl-2阻害剤の選択性比較

生物活性

製品説明 TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
ターゲット
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
体外試験

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell NYHNT25TT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnLlTY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[gcm0> MniwV2FPT0WU
human Ca9-22 cell NYiwUVlyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn\nTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlgzKG6P MX7TRW5ITVJ?
human CHL-1 cell NUXuXHJLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX7aN3VWUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjlibl2= MX\TRW5ITVJ?
human A549 cell NFy1Rm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXTVW5J6UW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvODlibl2= MUnTRW5ITVJ?
human RKO cell MljWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFvwTZFKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlE4KG6P NHnIRoFUSU6JRWK=
human GCIY cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHrTY5pcWKrdHnvckBw\iCqdX3hckBIS0m\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuPFMhdk1? NWDTS3VJW0GQR1XS
human BHT-101 cell M{LxS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NID4ZmxKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOS56MzDuUS=> NGH3eGtUSU6JRWK=
human Hs-578-T cell MkLIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEXoTYhKdmirYnn0bY9vKG:oIHj1cYFvKEi|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjNwNUmgcm0> MonBV2FPT0WU
human SK-UT-1 cell NGPDV5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX32WW5IUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjhwNkigcm0> MY\TRW5ITVJ?
human NB7 cell NEfoVIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLLXXVGUW6qaXLpeIlwdiCxZjDoeY1idiCQQkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU4zQCCwTR?= MXzTRW5ITVJ?
human YKG-1 cell NUf2SXpsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXxSXY1UW6qaXLpeIlwdiCxZjDoeY1idiC\S1etNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI6Njd4IH7N NIPMcGNUSU6JRWK=
human HuH-7 cell MlfnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGh2UC15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{KuPFIhdk1? M33JeXNCVkeHUh?=
human SAS cell MnPXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUD2eldSUW6qaXLpeIlwdiCxZjDoeY1idiCVQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{4yQCCwTR?= MnL5V2FPT0WU
human UACC-62 cell MlnsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKGi3bXHuJHVCS0NvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4{PSCwTR?= NUXHboc5W0GQR1XS
human AGS cell M4jibWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN5LkWzJI5O MnTrV2FPT0WU
human SK-MEL-30 cell NWTPSlIxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{PRO2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzdwOUegcm0> NIjDbJVUSU6JRWK=
human A427 cell NHrRZohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2\WXGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlY6KG6P NXHIOZVLW0GQR1XS
human DU-145 cell NFSwepdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGXXbm5KdmirYnn0bY9vKG:oIHj1cYFvKESXLUG0OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUzNjF|IH7N NV;nR5k2W0GQR1XS
human HCT-116 cell NXGyXYV2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIjaNYFKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi54NjDuUS=> NXK0NpEyW0GQR1XS
human A673 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnUTY5pcWKrdHnvckBw\iCqdX3hckBCPjd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOuPFUhdk1? NVjoOm9uW0GQR1XS
human SF126 cell MlvhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEK4cY1KdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVcvODdibl2= NVe4bZBYW0GQR1XS
human SW872 cell M4fC[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFrRTmRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVgvQSCwTR?= NEfiSVhUSU6JRWK=
human NCI-H1581 cell NX;UTnR{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW4NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY4NjZ2IH7N Ml[4V2FPT0WU
human SK-MEL-5 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NInXWYxKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwMkWgcm0> MlrFV2FPT0WU
human CP50-MEL-B cell M33CPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVvJcohq[mm2aX;uJI9nKGi3bXHuJGNRPTBvTVXMMWIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QS53OTDuUS=> NHH3OWFUSU6JRWK=
human YH-13 cell NGTrXpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnW[FV3UW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcxNjV7IH7N M{nBNHNCVkeHUh?=
human LXF-289 cell NWfEWXVIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Nk45PSCwTR?= M2nKVXNCVkeHUh?=
human MC-IXC cell M4Li[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe1MlM{KG6P NFfjbFRUSU6JRWK=
human NB14 cell Mkn4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mo\VTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;N{[uOFUhdk1? MkP0V2FPT0WU
human HEC-1 cell MnnBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NInDPVRKdmirYnn0bY9vKG:oIHj1cYFvKEiHQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFEvOzdibl2= M4Lke3NCVkeHUh?=
human U-87-MG cell NV;BWmR1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4Lrd2lvcGmkaYTpc44hd2ZiaIXtZY4hXS16Nz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgzNjJ2IH7N MXjTRW5ITVJ?
human HOS cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2mxc2lvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OESuO|Ehdk1? M17hSXNCVkeHUh?=
human HUTU-80 cell M{fWR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2n0b2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjBzIH7N NV:5V4VFW0GQR1XS
human A375 cell NEnnbnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFnRPY5KdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24PE45OyCwTR?= NELqOWZUSU6JRWK=
human A204 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Nz64OEBvVQ>? MXvTRW5ITVJ?
human GB-1 cell MmnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1H5SWlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm4MlY6KG6P M1XGe3NCVkeHUh?=
human MDA-MB-231 cell M4j5e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlrDTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMEiwO{DPxE1? MmPFV2FPT0WU
human SW982 cell M1;IWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvXTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVExPyEQvF2= NIjlboRUSU6JRWK=
human SW756 cell MnHCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml\OTY5pcWKrdHnvckBw\iCqdX3hckBUXzd3NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEzOzZizszN MVXTRW5ITVJ?
human MG-63 cell NYfnZ4czT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NULQUmlPUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF{NEig{txO MXXTRW5ITVJ?
human Daoy cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0NFc{KM7:TR?= MV3TRW5ITVJ?
human MDA-MB-453 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnFeotKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01PTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG1NVg5KM7:TR?= NUHCfJAxW0GQR1XS
human HT-144 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH\hXopKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUG0OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV{MEGg{txO NWfS[Zl5W0GQR1XS
human LoVo cell MmrDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnPHTY5pcWKrdHnvckBw\iCqdX3hckBNd1[xIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlA6OyEQvF2= NVrYNlduW0GQR1XS
human NY cell NVTiN4RkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zN{e2NkDPxE1? M171dHNCVkeHUh?=
human SW1783 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTd6MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlE{ODFizszN MWDTRW5ITVJ?
human A2780 cell Mne2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;xW4NKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTh2NjFOwG0> MnLsV2FPT0WU
human MDA-MB-361 cell NUXWeJhMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnizTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Mk[0JO69VQ>? M2jBRnNCVkeHUh?=
human RPMI-2650 cell NUPj[GhQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvMk[1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN6M{Gg{txO NXnrNm9MW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
細胞試験: [2]
- 合併
  • 細胞株: HDMECs
  • 濃度: 0 - 100 μM
  • 反応時間: 96 hours
  • 実験の流れ: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (参考用のみ)
動物試験:[3]
- 合併
  • 動物モデル: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • 投薬量: ~40 mg/kg
  • 投与方法: Administered via i.v. or i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% propylene glycol, 5% Tween 80, 65% D5W
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 573.7
化学式

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
別名 N/A
Smiles CC(C)C1=CC=CC=C1CC2=CC(=C(C(=C2O)O)O)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Bcl-2シグナル伝達経路

Bcl-2 Inhibitors with Unique Features

相関Bcl-2製品

Tags: TW-37を買う | TW-37 ic50 | TW-37供給者 | TW-37を購入する | TW-37費用 | TW-37生産者 | オーダーTW-37 | TW-37化学構造 | TW-37分子量 | TW-37代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID